TIDES® Oligonucleotide and Peptide Technology and Product Development

View PDF

Moving to Boston, MA, after four years in the western United States (Las Vegas and Carlsbad, CA), the Tides conference continues to be the must-attend event for the industry that grows in attendance each year. The 2010 agenda includes thought-provoking keynotes and featured presentations, a compelling regulatory session, and discussions with CBER, FDA, and European regulatory agency speakers. In separate tracks for each type of molecule, learn more from the new, full-day sessions on CMC manufacturing and analysis and a full day on formulation and delivery, as well as updates on compounds in development. Back by popular demand, expanded break-out discussion sessions and preconference courses offer behind-the-scenes insight into critical industry issues, and let you ask specific questions of experts in a small-group setting.

For the First Time: TIDES becomes an even more comprehensive program this year with the addition of the colocated “Oligonucleotide Therapeutics Discovery” conference. TIDES main conference attendees can also sit in on its sessions and those of the colocated “Nucleic Acids Technologies in Molecular Diagnostics” conference too. Consider sending a team from your discovery, preclinical, clinical, and manufacturing groups to take advantage of these concurrent sessions and content.

These events will be held at the Hynes Convention Center in Boston’s famed Back Bay area — just a few blocks from Newbury Street, the Prudential Center and Mall, and countless restaurants, not to mention many local academic/clinical institutions and industry R&D sites. TIDES offers a comprehensive program and ideal location for enjoyable and productive business and scientific consultations. This is your best way to gain a comprehensive update on developments in the peptide and oligonucleotide fields and to meet the people who can help move your program forward.

New This Year

Augment your experience by attending a site tour to see manufacturing facilities firsthand. Choose from a visit to Avecia OligoMedicines on Monday afternoon and/or to Alnylam Pharmaceuticals on Wednesday afternoon.

COLOCATED CONFERENCES

  • IBC’s sixth international Applications of Nucleic Acids Technologies in Molecular Diagnostics: Accelerating Product Development Through Cutting-Edge Regulatory, Business and Technology Strategies (27–28 April 2010)

  • IBC’s second annual Oligonucleotide Therapeutics Discovery: For Discovery, Preclinical and Early Development Scientists (26–28 April 2010)

Preconference Courses

  • Current Topics in Oligonucleotide Manufacturing: Managing the Manufacture of Novel Oligonucleotide Therapeutics

  • Bioanalytical Methods for the Determination of Therapeutic Oligonucleotides

  • Current Topics in the Analysis of Oligonucleotides in Support of Drug Development

  • Managing Analytical Development and Quality Control for Peptides

  • Oligonucleotide Lead Discovery and Candidate Selection

Expanded Break-Out Discussion Sessions

  • Regulatory Updates on Oligonucleotide Therapeutics and on Peptide Vaccines and Therapeutics

  • Follow-Up Discussion to Oligonucleotide CMC Manufacturing and Analysis Session

  • Applications of Mass Spectrometry to Synthetic Oligonucleotides

  • Intellectual Property Issues Relating to Therapeutic Oligonucleotides and Peptides

Keynote Presentations

“Synthetic Biologics: A New Class of Drugs for ‘Undruggable’ Targets” by Gregory L. Verdine, PhD, Erving professor of chemistry at Harvard University

“RNAi: Developing a New Therapeutic Platform” by John Maraganore, PhD, chief executive officer of Alnylam Pharmaceuticals, Inc.

“Noncoding RNAs As Drug Targets” by Claes R. Wahlestedt, MD, PhD, professor and director of neuroscience discovery at The Scripps Research Institute in Florida

Featured Presentations

“Deal Trends in Nucleic-Acid–Based Therapeutics: A Look at Past Deals and Thoughts on the Future” by Philip McGurk, PhD, senior director of business development at Pfizer Inc.

“Peptide Therapeutics: New Growth and Directions” by Janice M. Reichert, PhD, senior research fellow at Tufts Center for the Study of Drug Development and monoclonal antibodies editor in chief for Landes Bioscience

Leave a Reply